Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy.

Nabili V, Tan JW, Bhuta S, Sercarz JA, Head CS.

Head Neck. 2007 Oct;29(10):907-12.

PMID:
17563907
2.

Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy.

Prat A, Parera M, Reyes V, Peralta S, Cedrés S, Andreu J, Huguet P, del Campo JM.

Head Neck. 2008 May;30(5):680-3.

PMID:
17972317
3.

Trastuzumab for the treatment of salivary duct carcinoma.

Limaye SA, Posner MR, Krane JF, Fonfria M, Lorch JH, Dillon DA, Shreenivas AV, Tishler RB, Haddad RI.

Oncologist. 2013;18(3):294-300. doi: 10.1634/theoncologist.2012-0369. Epub 2013 Feb 21.

4.

Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial.

Lara PN Jr, Chee KG, Longmate J, Ruel C, Meyers FJ, Gray CR, Edwards RG, Gumerlock PH, Twardowski P, Doroshow JH, Gandara DR.

Cancer. 2004 May 15;100(10):2125-31.

5.

Salivary duct carcinoma--a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression.

Skálová A, Stárek, Kucerová V, Szépe P, Plank L.

Pathol Res Pract. 2001;197(9):621-6.

PMID:
11569926
6.

Salivary duct carcinoma of the parotid gland: is adjuvant HER-2-targeted therapy required?

Lee JS, Kwon OJ, Park JJ, Seo JH.

J Oral Maxillofac Surg. 2014 May;72(5):1023-31. doi: 10.1016/j.joms.2013.11.014. Epub 2013 Nov 22.

PMID:
24480767
7.

Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer.

Gasparini G, Gion M, Mariani L, Papaldo P, Crivellari D, Filippelli G, Morabito A, Silingardi V, Torino F, Spada A, Zancan M, De Sio L, Caputo A, Cognetti F, Lambiase A, Amadori D.

Breast Cancer Res Treat. 2007 Mar;101(3):355-65. Epub 2006 Jul 19.

PMID:
16850247
8.

Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases.

Jaehne M, Roeser K, Jaekel T, Schepers JD, Albert N, Löning T.

Cancer. 2005 Jun 15;103(12):2526-33.

9.

Invasive micropapillary salivary duct carcinoma: a distinct histologic variant with biologic significance.

Nagao T, Gaffey TA, Visscher DW, Kay PA, Minato H, Serizawa H, Lewis JE.

Am J Surg Pathol. 2004 Mar;28(3):319-26.

PMID:
15104294
10.

Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review.

Kaidar-Person O, Billan S, Kuten A.

Med Oncol. 2012 Jun;29(2):704-6. doi: 10.1007/s12032-011-9884-1. Epub 2011 Mar 6. Review.

PMID:
21380780
11.

Salivary duct carcinoma: what is already known, and can we improve survival?

Wee DT, Thomas AA, Bradley PJ.

J Laryngol Otol. 2012 Jul;126 Suppl 2:S2-7. doi: 10.1017/S0022215112000412. Epub 2012 Apr 12. Review.

PMID:
22495125
12.

Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.

Burris H 3rd, Yardley D, Jones S, Houston G, Broome C, Thompson D, Greco FA, White M, Hainsworth J.

J Clin Oncol. 2004 May 1;22(9):1621-9.

PMID:
15117984
13.

[Two cases of recurrent breast cancer with regional lymph node metastases showing a complete response to trastuzumab and paclitaxel treatment].

Ohsako T, Inoue K, Nagamoto N, Yoshida Y, Nakahara O.

Gan To Kagaku Ryoho. 2006 Sep;33(9):1301-3. Japanese.

PMID:
16969029
14.

HER-2/neu expression in primary and metastatic breast cancer.

Lower EE, Glass E, Blau R, Harman S.

Breast Cancer Res Treat. 2009 Jan;113(2):301-6. doi: 10.1007/s10549-008-9931-6. Epub 2008 Feb 14.

PMID:
18273700
15.

HER-2 profiling and targeting in prostate carcinoma.

Morris MJ, Reuter VE, Kelly WK, Slovin SF, Kenneson K, Verbel D, Osman I, Scher HI.

Cancer. 2002 Feb 15;94(4):980-6.

16.

Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598.

Langer CJ, Stephenson P, Thor A, Vangel M, Johnson DH; Eastern Cooperative Oncology Group Study 2598.

J Clin Oncol. 2004 Apr 1;22(7):1180-7. Epub 2004 Feb 23.

PMID:
14981103
17.

[Survival analysis and immunohistochemical study of HER-2 and AR (androgen receptor) expression in salivary duct carcinoma].

Otsuka K, Imanishi Y, Habu N, Sato Y, Shigetomi S, Fujii R, Sakamoto K, Tomita T, Fujii M, Kameyama K, Ogawa K.

Nihon Jibiinkoka Gakkai Kaiho. 2013 Sep;116(9):1024-32. Japanese.

PMID:
24191589
18.
19.

Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution.

Clay MR, Iberri DJ, Bangs CD, Cherry A, Jensen KC.

Am J Surg Pathol. 2013 Jan;37(1):120-7. doi: 10.1097/PAS.0b013e31826ab19d.

PMID:
23108020
20.

Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry.

Skálová A, Stárek I, Vanecek T, Kucerová V, Plank L, Szépe P, Di Palma S, Leivo I.

Histopathology. 2003 Apr;42(4):348-56.

PMID:
12653946

Supplemental Content

Support Center